Vera Therapeutics Inc. (VERA) Reports Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 6:30 AM EDTPhase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022 BK Virus and MAU868 key opinion leader webinar to be held Tuesday, March 29, 2022Management to host business update webcast today at 8:00 a.m. ET
BRISBANE, Calif., March 24, 2022 (GLOBE... More
